# Switching to the Wegovy pill: what the licence says Canonical URL: https://www.hemed.com/blog/switching-to-the-wegovy-pill Plain-text URL: https://www.hemed.com/blog/switching-to-the-wegovy-pill/llms.txt Published: 2026-10-22 Modified: 2026-10-22 Author: The HeMed clinical team Topic: Weight-loss treatment Topic URL: https://www.hemed.com/blog/topic/weight-loss-treatment Tags: Switching provider, Dosing Reading time: 11 min Publisher: HeMed (https://www.hemed.com/) ## Summary Moving to the tablet from another provider or another form: what the UK licence says, what a new prescriber reviews and what changes in your routine. ## Article Switching to the Wegovy pill (semaglutide tablets) takes one of two routes: a new provider, or a new form of the same medicine. Both are decisions for a prescriber. The UK licence sets out one transition. That transition is the move from the 2.4 mg weekly Wegovy injection to the 25 mg daily tablet, one week after the last injection. Why you move is between you and your prescriber. This article sets out what the licence says and what a new prescriber needs to know about you. It also covers how the tablet is taken. A licence is a medicine’s UK approval. Its rules sit in the Summary of Product Characteristics (SmPC), the document the regulator approves for each medicine. The regulator is the Medicines and Healthcare products Regulatory Agency (MHRA), which approved the tablet on 11 June 2026. ### What does switching to the Wegovy pill involve? Switching involves a prescriber’s assessment before anything changes. The Wegovy pill is a prescription-only medicine. A new provider means a new prescriber, who makes their own assessment. A new form means the move from the weekly injection to the daily tablet. The licence treats that move as a transition with its own rule. The tablet is licensed for adults with a body mass index (BMI) of 30 or more. The licence also covers a BMI of 27 to under 30 with at least one weight-related condition. BMI is your weight against your height. The licence does not describe a change of provider. It sets doses, timing and the checks a prescriber makes. Those apply whoever prescribes, and the sections below take them in turn. ### What does a new prescriber need to know? A new prescriber needs five things from you. - your current medicine and its dose - when you started it - the date of your last dose - how you have tolerated your current dose, including any side effects - any other medicines you take #### Why these matter The medicine and dose matter because the tablet licence sets its own dose schedule. It names only one direct transition, from the 2.4 mg injection. The date of your last dose matters because that transition starts one week after the last injection. How you have tolerated your dose matters because the tablet licence allows a dose to stay at the previous level if needed. Other medicines matter because the tablet may change how other oral medicines are absorbed. You will find the checks the licence asks for further down. #### What does the pharmacy regulator require? The General Pharmaceutical Council (GPhC) regulates pharmacies in Great Britain, including online pharmacies. Its guidance for pharmacies working at a distance says weight-management medicines are not suitable to be prescribed by a questionnaire model alone. For these medicines, the prescriber must not base the decision on a questionnaire alone. They must verify the information independently. For weight-management medicines, that means verifying your weight, height or BMI independently. The routes the guidance names are a video consultation, an in-person check, your clinical records or another provider such as your GP. A phone call is not an appropriate way to verify those measurements. The guidance also asks for your regular prescriber’s details, such as your GP, and your consent to contact them. The MHRA says a consultation with a healthcare professional must take place before a GLP-1 medicine is prescribed privately. GLP-1 medicines, the class the Wegovy pill belongs to, act like GLP-1, a gut hormone that affects appetite and blood sugar. So the assessment is the prescriber’s own, built from what you bring and what they verify. ### What does the licence say about moving from the injection to the tablet? The licence names one transition. People on the 2.4 mg once-weekly semaglutide injection can move to the 25 mg once-daily tablet, starting one week after their last injection. It sets no transition from any other injection dose. The licence adds a warning. The effect of switching between the tablet and the injection “cannot easily be predicted”. Its reason is that the amount of semaglutide your body absorbs from the tablet varies more than from the injection. The two forms are not taken together. A GLP-1 receptor agonist is a medicine that acts like GLP-1, the gut hormone described above. The injection licence says taking it with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended. #### What the licence sets for each move Each licence sets a transition from one form to the other. Move | What the licence says 2.4 mg weekly injection to the 25 mg daily tablet | Allowed. The tablet starts one week after the last injection. Any other injection dose to the tablet | Clinical decision. The licence sets no transition. The tablet’s own schedule starts at 1.5 mg. 25 mg daily tablet to the 2.4 mg weekly injection | Allowed under the injection licence. The injection starts the day after the last tablet. Tablet and injection together | Not taken together. The injection licence says taking it with other semaglutide-containing products is not recommended. The table summarises what each licence sets. Where it says clinical decision, the licence is silent. Whether and when you move is a decision for your prescriber. #### Injection doses other than 2.4 mg The injection licence builds the dose up over 16 weeks: 0.25 mg, 0.5 mg, 1 mg and 1.7 mg, then 2.4 mg. It also allows a 7.2 mg dose for adults with obesity. That higher dose is allowed if needed, after a minimum of 4 weeks on 2.4 mg. The tablet licence names a transition only from 2.4 mg. If you are on another injection dose, where the tablet starts is a clinical decision within the tablet’s own schedule, which begins at 1.5 mg. ### What if you take a different weight-management medicine now? The licence sets no transition from any other medicine to the Wegovy pill. The MHRA says to consult a healthcare professional before switching from one GLP-1 medicine to another. That includes switching between brands that contain the same type of GLP-1. The regulator gives its reason. GLP-1 medicines vary in how strong they are, how they are used and the conditions they can be used for. Switching without medical advice may increase the risk of side effects or make the treatment less effective. Mounjaro (tirzepatide) is one example. Its licence describes tirzepatide as a GIP and GLP-1 receptor agonist, and says nothing about moving to or from semaglutide. GIP stands for glucose-dependent insulinotropic polypeptide, a second gut hormone. #### The tablet’s own schedule The licence gives one dose schedule for the tablet. It begins at 1.5 mg once daily, then 4 mg, 9 mg and 25 mg, with at least one month at each level. When the tablet starts is a decision for your prescriber. If you move from another medicine, the licence names no other starting point. Its one exception is the 2.4 mg Wegovy injection, covered above. ### How is the tablet taken? You take the tablet once a day, on an empty stomach, after a fast of at least 8 hours. Swallow it whole with a sip of water, up to 120 mL, which is about half a glass. Then wait at least 30 minutes before eating, drinking or taking other medicines by mouth. #### The empty-stomach rule Waiting less than 30 minutes lowers how much semaglutide your body absorbs. Do not split, crush or chew the tablet. It is not known whether that changes absorption. The licence sets no time of day. The injection licence allows the weekly dose at any time of day, with or without meals. #### If you miss a dose Skip the missed tablet and take the next dose the following day. One tablet a day only, and never two tablets to reach a higher dose. #### Other medicines The tablet slows stomach emptying. That may change how your body absorbs other medicines taken by mouth. Take other tablets after the 30-minute wait. If you take levothyroxine, a thyroid hormone replacement, the licence says to consider thyroid monitoring. ### What does the licence ask a prescriber to check? The licence lists conditions and medicines a prescriber weighs before and during treatment. Tell your new prescriber about each one that applies to you, and about anything that happened on your current treatment. The main ones are below. #### Conditions the licence names - A history of pancreatitis (inflammation of the pancreas). Semaglutide has not been studied in people with that history and is used with caution. If pancreatitis is suspected, semaglutide is stopped. If it is confirmed, semaglutide is not restarted. - Diabetic retinopathy (damage to the back of the eye caused by diabetes). Rapid improvement in blood sugar control has been associated with a temporary worsening, so the licence asks for close monitoring. - Fluid loss. Nausea, vomiting and diarrhoea can cause dehydration. In rare cases dehydration can worsen kidney function. So the licence asks you to take precautions against fluid loss. #### Medicines, procedures and your current dose - Insulin or a sulfonylurea (a type of diabetes tablet). Taking semaglutide with either may raise the risk of hypoglycaemia (low blood sugar). The licence says reducing the insulin or sulfonylurea dose when starting can lower that risk. - Levothyroxine. In a study, total exposure to the thyroid hormone rose by 33% when taken with semaglutide. So the licence says to consider thyroid monitoring. - A planned operation under general anaesthetic (being put to sleep) or deep sedation. The licence asks for the risk of food remaining in the stomach to be weighed beforehand. So tell the team you take semaglutide. - Side effects on your current dose. The tablet licence allows a dose to stay at the previous level if needed. So your prescriber needs to know what you have tolerated. Only use medicine from a registered prescriber and a legitimate pharmacy. The MHRA says the only way to be sure of a genuine GLP-1 medicine is a legitimate pharmacy with a prescription. That includes online pharmacies, and you can check a pharmacy in Great Britain on the GPhC register. ### How does HeMed fit in? HeMed starts with a blood test. We measure 10 metabolic markers across four systems from a needle-free blood test at home. If you’ve been on treatment within the last 2 months, the baseline test is your choice. Your clinician can assess you from proof of your prescription and your medical history. A clinician reviews your blood test first. If they approve treatment, we deliver it the next working day, discreetly packaged, with delivery included in your plan. Your dose moves on how you are doing, not on a calendar. If side effects are still settling on a lower dose, your clinician can hold that dose before any increase, as the licence allows. No step comes sooner than the licence minimum of one month. A weekly in-app check-in, reviewed by clinicians, so your plan can be adjusted when it needs to be. A retest every 6 months shows what’s actually changing. The Wegovy pill is a prescription medicine for weight management. Whether it’s right for you is a clinical decision, made from your health information and your baseline blood test. ### Frequently asked questions **Do I have to stop my current treatment while I switch?** Keep taking your current treatment as prescribed. A clinician reviews your health information and your current treatment first. They confirm your HeMed plan before anything changes. For the move from the 2.4 mg injection, the licence sets one week after the last injection. The Wegovy tablet leaflet says: do not stop using this medicine without talking to your doctor. **What dose does the tablet start at?** The licence starts the tablet at 1.5 mg once daily. Each level lasts at least one month before the next: 4 mg, 9 mg, then 25 mg. The one exception it names is the move from the 2.4 mg weekly injection, which goes to the 25 mg tablet. Where you start is a clinical decision within those rules. **What if I have no records from my current provider?** A prescriber assesses you from what you bring and what they can verify. The pharmacy regulator requires independent verification of your weight, height or BMI, not a questionnaire alone. The MHRA requires a consultation before a GLP-1 medicine is prescribed privately. Bring what you have: your medicine, its dose, your start date and the date of your last dose. **Can I take the tablet and the injection together?** No. The injection licence says taking it with other semaglutide-containing products is not recommended. Each licence sets a transition from one form to the other. From the 2.4 mg injection, the tablet starts one week after the last injection. **Will I have to start from the beginning again?** No, not for the sake of it. Your clinician reviews where you are, including your current treatment and dose, and continues it where that is right for you. What suits you is a clinical decision. **How often is the blood test repeated?** A retest every 6 months shows what’s actually changing. If you’ve been on treatment within the last 2 months, the baseline test is your choice. **Who is HeMed for?** HeMed is a clinician-led weight loss and metabolic health service for men in the UK, built around an at-home blood test. HeMed provides clinician-led weight management. Treatment is prescription-only and is prescribed only where a clinician decides it is suitable. This page is general health information, not medical advice. If you are worried about symptoms, speak to your GP, or use NHS 111. Next step: see what the HeMed blood test measures. Sources (7) - Novo Nordisk, Wegovy 25 mg tablets (semaglutide) Summary of Product Characteristics, sections 4.1, 4.2, 4.4 and 4.5 (text revised June 2026). electronic medicines compendium. medicines.org.uk/emc/product/102347/smpc. Accessed 22 October 2026. - MHRA, “First GLP-1 tablet for weight loss approved in the UK”, 11 June 2026. gov.uk/government/news. Accessed 22 October 2026. - General Pharmaceutical Council, “Guidance for registered pharmacies providing pharmacy services at a distance, including on the internet”, February 2025, section 4.2, items j, k and l (pages 23 to 25). pharmacyregulation.org. Accessed 22 October 2026. - MHRA, “GLP-1 medicines for weight loss and diabetes: what you need to know”, updated 5 February 2026. gov.uk/government/publications. Accessed 22 October 2026. - Novo Nordisk, Wegovy FlexTouch (semaglutide) Summary of Product Characteristics, sections 4.2 and 4.5 (text revised September 2026). electronic medicines compendium. medicines.org.uk/emc/product/13800/smpc. Accessed 22 October 2026. - Eli Lilly, Mounjaro KwikPen (tirzepatide) Summary of Product Characteristics, sections 4.2 and 5.1 (text revised August 2026). electronic medicines compendium. medicines.org.uk/emc/product/15481/smpc. Accessed 22 October 2026. - Novo Nordisk, Wegovy tablets Patient Information Leaflet, section 3 (last revised June 2026). electronic medicines compendium. medicines.org.uk/emc/product/102347/pil. Accessed 22 October 2026. Numbered markers in the page text link to these entries. Statistics describe populations, not any one person’s results. --- This is the plain-text version of the article at https://www.hemed.com/blog/switching-to-the-wegovy-pill, generated from the page on 2026-10-22. It is for information only and is not medical advice. Whether any treatment is right for a person is a clinical decision. Statistics describe populations, not any one person's results.